TFAM and prostate carcinoma: In some cases (e.g., liver in extrahepatic cholestasis and hepatocellular carcinoma, melanoma cell lines, or prostatic cancer cell lines treated with arsenic), compromised levels of TFAM may result in mtDNA mutations or deletions [267,288,289,295].